In a recent study published in the journal Clinical Infectious Diseases researchers found that a HIV prevention treatment successfully reduced the early development of HIV infections.
Preexposure prophylaxix (PrEP) is the name of the regimen in use, and it involves dosing antiviral medication to those who are at risk for contracting the HIV Disease in order to stop the infections from spreading before they can settle in the organism to cause permanent damage.
It is the most comprehensive PrEP evaluation since the Food and Drug Administration (FDA) approved the drug back in 2012. The substance was administered daily under the form of a pill called Truvada. It is also the first experiment of its kind that took place outside scientific settings.
During its 32 months span, the intensive study’s experts at Kaiser Permanente San Francisco Medical Center noticed that among the 673 patients under Truvada treatment no new cases of infection developed. Most of the participants were gay men at high risk for contracting the disease. Researchers also tested what happened when the subjects have taken the drug before and after they had sex instead on a daily basis. But the results indicated the same thing: the antiviral medication is highly effective.
In previous researches, conducted in scientific settings, the experts found that the drug could put an end to up to 92% of HIV infections. The drug is thought to be more effective when taken consistently.
Because of the drug’s effectiveness, critics have raised concerns that Truvada will smooth the path for unsafe sex. However, healthcare officials and gay rights activists fully support the the use of the new drug, saying it may be a great step towards the prevention of HIV spread.
Truvada use is encouraged by both the World Health Organization and the Centers for Disease Control and Prevention for groups that are at risk for contracting the disease, such as injection drugs addicts, transgender women, gay men as well as any individual with a HIV positive partner.
The researchers at Kaiser Permanente San Francisco Medical Center, however, emphasized that the drug should be widely available and appropriately recognized by everyone who is at risk for contracting HIV.
Photo credits: wikipedia